is a senior reporter covering technology, gaming, and more. He joined The Verge in 2019 after nearly two years at Techmeme. Google’s Personal Intelligence feature, which lets Gemini pull data from ...
SHELTON, Conn.--(BUSINESS WIRE)--Pitney Bowes today announced the launch of a new Temu integration within ShipAccel®, its cloud-based shipping and order management solution. The integration is ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...
Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
The Gmail mobile apps lack a handful of features found on the website, but Google is now adding the ability to create new labels on Android. Once available, open the navigation drawer for “Create ...
After testing the feature since December, Google is finally rolling out “create and manage labels” to Gmail for Android. Previously exclusive to desktop and iOS, this update allows Android users to ...
Gmail for Android is finally catching up to the iOS version with the addition of a useful feature. You can now create new labels directly on the Android app. The Android app still doesn’t allow ...
Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results